2-(5-Chloropyrazin-2-yl)-1-(6-methoxypyridazin-3-yl)-5-(trifluoromethoxy)benzimidazole | 1312307-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 2-(5-Chloropyrazin-2-yl)-1-(6-methoxypyridazin-3-yl)-5-(trifluoromethoxy)benzimidazole
• CAS: 1312307-97-3
• 化学式: C₁₇H₁₀ClF₃N₆O₂
• 分子量: 422.754
• InChiKey: CQTXWNNBAWBDAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  87.8
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• NOVEL ANTIPLATELET AGENT
  申请人：Sato Hiroshi

  公开号：US20120258951A1

  公开（公告）日：2012-10-11

  The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: wherein, X is N, or CR 1d , X b1 -X b5 are the same or different, and are nitrogen or carbon, R 1a -R 1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino, R 2 is an optionally substituted aryl or an optionally substituted heteroaryl, R 3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.

  本发明涉及一种新型抗血小板药剂和一种新型化合物，该化合物是药剂的活性成分。本发明提供了包含由下式I表示的化合物的抗血小板药剂：其中，X为N或CR1d，Xb1-Xb5相同或不同，为氮或碳，R1a-R1d相同或不同，为氢，可选择地取代的烷基，可选择地取代的烷氧基，可选择地取代的烷基硫基，烯基，环烷基，卤素，氰基，或羟基，或者可选择地被1或2个烷基氨基取代，R2为可选择地取代的芳基或可选择地取代的杂环芳基，R3为可选择地取代的芳基或可选择地取代的杂环芳基，或其药用可接受盐作为活性成分。
• NOVEL ANTI-PLATELET AGENT
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2518066A1

  公开（公告）日：2012-10-31

  The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: wherein, X is N, or CR1d, Xb1-Xb5 are the same or different, and are nitrogen or carbon, R1a-R1d are the same or different, and are hydrogen, an optionally substituted aklyl, an optionally substituted alkoxy, an optionally substituted akylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, R3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.

  本发明涉及一种新型抗血小板药剂和作为该药剂活性成分的新型化合物。本发明提供的抗血小板药剂由式 I 所代表的化合物组成： 其中 X是N，或CR1d、 Xb1-Xb5相同或不同，且为氮或碳、 R1a-R1d 相同或不同，并且是氢、任选取代的烷基、任选取代的烷氧基、任选取代的烷硫基、烯基、环烷基、卤素、氰基或羟基或任选被 1 或 2 个烷基氨基取代、 R2 是任选取代的芳基或任选取代的杂芳基、 R3 是任选取代的芳基或任选取代的杂芳基，或 作为活性成分的药学上可接受的盐。
• US8703760B2
  申请人：——

  公开号：US8703760B2

  公开（公告）日：2014-04-22
• US9533983B2
  申请人：——

  公开号：US9533983B2

  公开（公告）日：2017-01-03